The Phase III DIAMOND trial met both its primary and secondary endpoints of reducing tics in both children and adult patients ...

CDC staff received an email this week telling them to avoid using more than a dozen terms or words-- including "health equity ...

Ecopipam showed statistical significance in treating Tourette syndrome versus a placebo for both its primary efficacy ...

In the Phase III trial, 41.9% of pediatric Tourette syndrome patients relapsed after ecopipam treatment, as compared with ...

Neurodevelopmental disorders company GRIN Therapeutics, an affiliate of the Blackstone Life Sciences portfolio company ...

Chicago, USA-based Emalex Biosciences announced positive top-line data from its Phase III registrational study of ecopipam, a ...